Renalytix AI plc

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Earnings data Q4 2022

Earnings data Q1 2023

LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

Renalytix has been fundraising successfully, extending its runway. Sales growth is strong albeit from a tiny base. Dozens of provider contracts are now in place across the U.S., though.

Renalytix: More Progress But Still Risky

LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, Utah. Due to the format of this event there are no formal company presentations. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG (info@btig.com).

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

Renalytix announces a c.$20.3 million private placement

Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

Renalytix Plc (NASDAQ:RNLX ) Q1 2023 Earnings Conference Call November 30, 2022 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - Chief Financial Officer Thomas McLain - President Fergus Fleming - Chief Technology Officer Conference Call Participants Dan Arias - Stifel Mark Massaro - BTIG Yi Chen - HCW Operator Good morning and welcome to the Renalytix Conference Call to review First Quarter Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mode.

Renalytix Plc (RNLX) Q1 2023 Earnings Call Transcript

LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2022.

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023

Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, and an observed early reduction in albumin to creatine ratio levels in the low and intermediate risk groups.

Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease

NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company's website at https://investors.renalytix.com or via the webcast registration link below beginning at 3:35 p.m. Eastern Time on November 16, 2022.

Renalytix to Present at Stifel Healthcare Conference

Renalytix Plc (NASDAQ:RNLX ) Q4 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO Thomas McLain - President O. James Sterling - CFO Michael J.

Renalytix Plc (RNLX) Q4 2022 Earnings Call Transcript

LONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full year results for the twelve months ended 30 June 2022.

Renalytix Reports Full Year Fiscal 2022 Results

NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost economics for Medicare population Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost economics for Medicare population

KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology

LONDON and SALT LAKE CITY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately.

Renalytix Announces Change to Board of Directors

NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company's website at https://investors.renalytix.com beginning at 7:00 a.m. Eastern Time on September 12, 2022.

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

Renalytix has a great product but a lousy cost base. I think that will force it to raise lots of new funds, diluting or wiping out common shareholders.

Renalytix: The Investment Case Is Shot

Renalytix Plc (NASDAQ:RNLX ) Q3 2022 Earnings Conference Call June 30, 2022 8:30 AM ET Company Participants James McCullough - Chief Executive Officer Tom McLain - President Jim Sterling - Chief Financial Officer Peter DeNardo - Capcomm Partners Conference Call Participants Dan Arias - Stifel Randy Baron - Pinnacle Mark Massaro - BTIG Yi Chen - HC Wainwright Jens Lindqvist - Investec Operator Good morning and welcome to the Renalytix conference call to review third quarter fiscal year 2022 financial results. At this time, all participants are in a listen-only mode.

Renalytix (RNLX) CEO, James McCullough on Q3 2022 Results - Earnings Call Transcript

LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended March 31, 2022.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30

Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly progressing chronic kidney disease Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly progressing chronic kidney disease

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

Agrify

CuriosityStream

By and large penny stocks deservedly have a bad rap, but right now selective attention to what Wall Street has to say makes sense for buyers. The post 3 Penny Stocks That Wall Street Thinks Are Undervalued appeared first on InvestorPlace.

3 Penny Stocks That Wall Street Thinks Are Undervalued

Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

Real-world clinical utility in 1,112 patients tested with KidneyIntelX

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®

NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Renalytix Plc ("Renalytix" or the "Company") (NASDAQ: RNLX).  Such investors are advised to contact Robert S.

News for Renalytix AI plc Stock (RNLX)